ClinicalTrials.gg
RecruitingNCT07733271Updated Jul 29, 2026

Robot-Assisted Closed Reduction and Internal Fixation for Extra-Articular Distal Tibial Fractures

An interventional study of Robot-assisted closed reduction and Traditional surgeon-led reduction in Distal Tibial Fracture and Tibial Fractures, sponsored by Beijing Jishuitan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Beijing Jishuitan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to evaluate the clinical efficacy and safety of an intelligent fracture reduction robot system in treating extra-articular distal tibial fractures. Traditional manual bone setting depends heavily on a surgeon's experience, which can sometimes lead to inconsistent alignment and increased radiation exposure. This clinical trial compares robot-assisted closed reduction against the traditional surgeon-led method. The primary goal is to determine if the robotic system improves the rate of accurate fracture alignment (excellent and good reduction rate) and helps patients recover better.

02

Conditions studied

  • Distal Tibial Fracture
  • Tibial Fractures

Browse trials for

03

In context

Tibial Fractures

135 studies on the registry are indexed under Tibial Fractures; 37 are open to participants now.

This study's planned enrollment of 60 is close to the median of 65 across 91 interventional studies indexed under Tibial Fractures.

Browse Tibial Fractures studies →

Lead sponsor

Beijing Jishuitan Hospital is the lead sponsor of 44 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral, acute, closed distal tibial fractures (Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association AO/OTA 43-A)
  • Time from injury to surgery \< 21 days
  • Able to walk independently before injury (assistive devices allowed)

Exclusion criteria

Exclusion Criteria:

  • Open fractures or multiple severe traumas requiring priority treatment
  • Asymmetrical lower extremities, or prior malunion of the ipsilateral tibia, or pre-existing deformities significantly affecting rotation/length evaluation
  • Ipsilateral fractures combined with other sites
  • Pathological fractures (tumor/metabolic)
  • Prior complex implants in place or previous surgeries significantly affecting evaluation
  • Active infection or severe systemic medical (unable to tolerate anesthesia/surgery)
  • Cognitive impairment, poor compliance, pregnancy, or lactation
  • Poor local skin conditions (e.g., obvious blisters, severe soft tissue injury)
  • Deemed unsuitable by the investigator (e.g., unable to follow up as planned) or refused randomization/enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Robot-Assisted Group

    Device: Robot-assisted closed reduction

  • Active comparator
    Traditional Group

    Procedure: Traditional surgeon-led reduction

Interventions

  • DeviceRobot-assisted closed reduction

    The patient undergoes automated or human-robot collaborative closed fracture reduction powered by an intelligent robotic system. The system integrates deep-learning-based bone segmentation, automatic reduction planning, and a self-adaptive 2D-3D image registration framework to achieve sub-millimeter positioning feedback and force-position collaborative security gates. Following successful reduction, the fracture is fixed with a distal tibial locking plate via the minimally invasive percutaneous plate osteosynthesis (MIPO) technique.

  • ProcedureTraditional surgeon-led reduction

    The patient undergoes conventional closed or open fracture reduction performed entirely by the surgical team based on traditional clinical experience under ordinary C-arm fluoroscopic guidance. Internal fixation is achieved using standard distal tibial locking plates or intramedullary nails according to the surgeon's choice and standard of care.

06

What researchers measure

Primary outcomes

  1. Rate of Excellent or Good Closed Fracture Reduction Assessed by Postoperative Low-Dose CT-Based 3D Quantitative Reduction Grading Criteria

    The percentage of patients achieving "Excellent" or "Good" anatomical closed reduction. Reduction quality is measured on post-op CT via RadiAnt DICOM Viewer and 3D Slicer based on the worst-performing of 3 dimensions: 1. Separation/shortening displacement: Excellent (≤3mm), Good (\>3-5mm), Fair (\>5-10mm), Poor (\>10mm). 2. Angulation deformity: Excellent (≤3°), Good (\>3-5°), Fair (\>5-10°), Poor (\>10°). 3. Rotational deformity: Excellent (≤3°), Good (\>3-5°), Fair (\>5-10°), Poor (\>10°). The final reduction grade is determined by the lowest category among these parameters, and the primary outcome represents the proportion of patients graded as Excellent or Good.

    Time frame: From completion of surgery to postoperative low-dose CT assessment, assessed up to 2 weeks after surgery

Secondary outcomes

  1. Total Operation Time Measured in Minutes

    Total operation time will be measured in minutes and defined as the duration from initial skin incision to completion of skin closure.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  2. Number of Intraoperative C-Arm Fluoroscopy Shots

    The number of intraoperative fluoroscopy shots taken using the C-arm during the surgical procedure will be recorded.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  3. Intraoperative Blood Loss Measured in Milliliters

    The estimated total volume of blood loss during the surgical procedure will be recorded in milliliters.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  4. Length of Hospital Stay Measured in Days

    The length of hospital stay will be recorded in days from admission to hospital discharge.

    Time frame: From hospital admission to hospital discharge, assessed up to 30 days

  5. Robot-Assisted Reduction Planning and Execution Time Measured in Minutes in the Experimental Group

    For participants assigned to the experimental group, the robot-assisted reduction planning and execution time will be recorded in minutes. This time is defined as the duration from completion of robotic arm setup to completion of the reduction maneuver.

    Time frame: From initial skin incision to completion of the reduction maneuver, assessed up to 8 hours

  6. Time to Radiographic Fracture Union Assessed by Standard X-Ray

    Time to radiographic fracture union will be measured in weeks using standard anteroposterior and lateral X-rays. Fracture union is defined as cortical bridging in at least 3 of 4 cortices with no significant pain during weight-bearing. Low-dose CT may be used to confirm fracture union in uncertain cases.

    Time frame: From completion of surgery to the first documented radiographic evidence of fracture union, assessed up to 12 months after surgery

  7. Radiographic Fracture Union Rate Assessed by Standard X-Ray

    The percentage of participants achieving radiographic fracture union will be assessed using standard anteroposterior and lateral X-rays. Low-dose CT may be used to confirm fracture union in uncertain cases.

    Time frame: From completion of surgery to the first documented radiographic evidence of fracture union, assessed up to 12 months after surgery

  8. Foot and Ankle Ability Measure-Activities of Daily Living Score

    The Foot and Ankle Ability Measure-Activities of Daily Living (FAAM-ADL) score is used to assess the functional status of patients with foot and ankle disorders. The subscale consists of 21 items, with a maximum total raw score of 84. The scores are converted into a percentage score ranging from 0% to 100%, where a higher score indicates a higher level of functional ability.

    Time frame: From baseline to 1 month, 3 months, 6 months and 12 months after surgery

  9. Lower Extremity Functional Scale Score

    The Lower Extremity Functional Scale (LEFS) is used to evaluate the patient's lower extremity function and ability to perform everyday tasks. The scale contains 20 items with a total raw score ranging from 0 to 80, where a higher score represents better functional status.

    Time frame: From baseline to 1 month, 3 months, 6 months and 12 months after surgery

  10. EuroQol 5-Dimension 5-Level Health Index

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire evaluates health-related quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The raw response is converted into a health state index score typically ranging from 0 (representing death) to 1 (representing perfect health), with higher scores reflecting better overall quality of life.

    Time frame: From baseline to 1 month, 3 months, 6 months and 12 months after surgery

  11. EuroQol Visual Analogue Scale Score

    The EuroQol Visual Analogue Scale (EQ VAS) provides a quantitative measure of the patient's self-rated overall health status. The score is recorded on a visual scale ranging from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: From baseline to 1 month, 3 months, 6 months and 12 months after surgery

  12. Incidence of Intraoperative Complications

    The percentage of participants experiencing intraoperative complications, including neurovascular injury, cortical perforation, abnormal bleeding, device failure, registration failure requiring manual takeover or change of reduction strategy, will be recorded.

    Time frame: From initial skin incision to completion of skin closure, assessed up to 8 hours

  13. Incidence of Postoperative Complications

    The percentage of participants experiencing postoperative complications, including wound problems or infection, thrombotic events, internal fixation failure, or loss of reduction, will be recorded.

    Time frame: From completion of surgery to postoperative complication assessment, assessed up to 12 months after surgery

  14. Incidence of Reoperation

    The percentage of participants requiring reoperation after the index surgery will be recorded.

    Time frame: From completion of surgery to reoperation assessment, assessed up to 12 months after surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 39 interventional studies with no phase under Tibial Fractures, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 80. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 29, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07733271
Lead sponsor
Beijing Jishuitan Hospital
Collaborators
Aerospace Center Hospital
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Chunpeng Zhao, MD / Chief Physician
Contact
zcpllza2008@163.com
+86 18610012704

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion